| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10067-014-2589-Z |
| P698 | PubMed publication ID | 24733249 |
| P50 | author | Luca Cantarini | Q30505846 |
| Orso Maria Lucherini | Q31159907 | ||
| Giuseppe Lopalco | Q38544880 | ||
| Florenzo Iannone | Q38544900 | ||
| Giovanni Lapadula | Q38544910 | ||
| Donato Rigante | Q87442620 | ||
| Laura Coladonato | Q117244059 | ||
| P2093 | author name string | Antonio Vitale | |
| P2860 | cites work | A proposed classification of the immunological diseases | Q21144701 |
| IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis | Q23912578 | ||
| Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature | Q31145072 | ||
| Behçet's disease. | Q33755094 | ||
| Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients | Q33774951 | ||
| Immunology and functional genomics of Behçet's disease | Q35549184 | ||
| Behcet's disease | Q35983466 | ||
| Behçet's disease: treatment of mucocutaneous lesions. | Q36226435 | ||
| Interferon therapy in rheumatic diseases: state-of-the-art 2010. | Q37671579 | ||
| Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab | Q38097750 | ||
| A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome. | Q40591437 | ||
| Adalimumab: a new modality for Behçet's disease? | Q42844975 | ||
| Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. | Q44457827 | ||
| Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases | Q45794317 | ||
| Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. | Q45978191 | ||
| A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. | Q51439320 | ||
| Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. | Q52522262 | ||
| Cytokines and Behcet's disease | Q57217995 | ||
| Anakinra treatment in drug-resistant Behcet’s disease: a case series | Q58326155 | ||
| Successful use of canakinumab in a patient with resistant Behçet's disease | Q58326230 | ||
| Tocilizumab treatment for neuro-Behcet's disease, the first report | Q61696886 | ||
| Tocilizumab may be a potential addition to our weapons against neuro-Behçet’s disease | Q61696935 | ||
| A study of cytokines in burn blister fluid related to wound healing | Q71711478 | ||
| Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction | Q80955835 | ||
| Refractory neuro-Behçet treated by tocilizumab: a case report | Q95421252 | ||
| P433 | issue | 6 | |
| P921 | main subject | tocilizumab | Q425154 |
| Behçet's disease | Q911427 | ||
| P304 | page(s) | 1141-1143 | |
| P577 | publication date | 2014-04-15 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab | |
| P478 | volume | 34 |
| Q40045785 | Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review |
| Q38677010 | Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study. |
| Q38653449 | Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review |
| Q40204739 | IL-6 blockade in the management of non-infectious uveitis |
| Q35133812 | Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives |
| Q42730515 | Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future |
| Q38841182 | Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease |
| Q38830790 | New therapeutic solutions for Behçet's syndrome |
| Q38525874 | Pathogenesis of Behçet's disease: autoinflammatory features and beyond |
| Q36207025 | Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease |
| Q47859067 | Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease |
| Q47613523 | Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy |
| Q92538442 | Treating the Different Phenotypes of Behçet's Syndrome |
| Q37624811 | Update on the Medical Management of Gastrointestinal Behçet's Disease. |
| Q90473546 | Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents |
Search more.